Angiotensin converting enzyme is the main contributor to angiotensin I–II conversion in the interstitium of the isolated perfused rat heart
- 1 May 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 19 (5) , 959-965
- https://doi.org/10.1097/00004872-200105000-00017
Abstract
Recent studies in homogenized hearts suggest that chymase rather than angiotensin converting enzyme (ACE) is responsible for cardiac angiotensin I to angiotensin II conversion. We investigated in intact rat hearts whether (i) enzymes other than ACE contribute to angiotensin I to angiotensin II conversion and (ii) the localization (endothelial/extra-endothelial) of converting enzymes. We used a modified version of the rat Langendorff heart, allowing separate collection of coronary effluent and interstitial fluid. Hearts were perfused with angiotensin I (arterial concentration 5-10 pmol/ml) under control conditions, in the presence of captopril (1 micromol/l) or after endothelium removal with 0.2% triton X-100. Endothelium removal was verified as the absence of a coronary vasodilator response to 10 nmol bradykinin. Angiotensin I and angiotensin II were measured in coronary effluent and interstitial fluid with sensitive radioimmunoassays. In control hearts, 45% of arterial angiotensin I was metabolized during coronary passage, partly through conversion to angiotensin II. At steady-state, the angiotensin I concentration in interstitial fluid was three to four-fold lower than in coronary effluent, while the angiotensin II concentrations in both fluids were similar. Captopril and endothelium removal did not affect coronary angiotensin I extraction, but increased the interstitial fluid levels of angiotensin I two- and three-fold, respectively, thereby demonstrating that metabolism (by ACE) as well as the physical presence of the endothelium normally prevent arterial angiotensin I from reaching similar levels in coronary effluent and interstitial fluid. Captopril, but not endothelium removal, greatly reduced the angiotensin II levels in coronary effluent and interstitial fluid. With the ACE inhibitor, the angiotensin II/I ratios in coronary effluent and interstitial fluid were 83 and 93% lower, while after endothelium removal, the ratios were 33 and 71% lower. In the intact rat heart, ACE is the main contributor to angiotensin I to angiotensin II conversion, both in the coronary vascular bed and the interstitium. Cardiac ACE is not limited to the coronary vascular endothelium.Keywords
This publication has 22 references indexed in Scilit:
- Functional Importance of Angiotensin-Converting Enzyme–Dependent In Situ Angiotensin II Generation in the Human ForearmHypertension, 2000
- Vasoconstriction by in situ formed angiotensin II: role of ACE and chymaseCardiovascular Research, 1999
- Evidence for Angiotensin-Converting Enzyme– and Chymase-Mediated Angiotensin II Formation in the Interstitial Fluid Space of the Dog Heart In VivoCirculation, 1999
- Dual pathway for angiotensin II formation in human internal mammary arteriesBritish Journal of Pharmacology, 1998
- Alternative pathways of angiotensin II production in the human saphenous veinBritish Journal of Pharmacology, 1998
- Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic heartsBiochemical Journal, 1998
- Angiotensin II-Forming Activity in a Reconstructed Ancestral ChymaseScience, 1996
- Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.Journal of Clinical Investigation, 1995
- Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.Journal of Clinical Investigation, 1993
- Angiotensin II-forming pathways in normal and failing human hearts.Circulation Research, 1990